Brief: Amneal And Shilpa Announce U.S. FDA Approval Of Boruzu™
05/09/2024 21:27
Sept 5 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL AND SHILPA ANNOUNCE U.S. FDA APPROVAL OF BORUZU™,
THE
FIRST READY-TO-USE VERSION OF BORTEZOMIB FOR SUBCUTANEOUS
ADMINISTRATION
* AMNEAL PHARMACEUTICALS: BORUZU IS EXPECTED TO LAUNCH WITH
A
UNIQUE J-CODE IN Q2 OF 2025
Source text for Eikon: ID:nBw7lsZTca
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study